-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Silmitasertib in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Silmitasertib in Basal Cell Carcinoma (Basal Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SynKIR-110 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SynKIR-110 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SynKIR-110 in Ovarian Cancer Drug Details: SynKIR-110 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Prostate Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Prostate Cancer Drug Details: Pidnarulex is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Peritoneal Cancer Drug Details: Pidnarulex is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Breast Cancer Drug Details: Pidnarulex is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pidnarulex in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Solid Tumor Drug Details: Pidnarulex is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pidnarulex in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pidnarulex in Pancreatic Cancer Drug Details: Pidnarulex is under development for the treatment of relapsed/refractory haematological...
-
Product Insights
Biliary Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Biliary Tumor - Drugs In Development, 2023’, provides an overview of the Biliary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Community Acquired Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community Acquired Pneumonia - Drugs In Development, 2023’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...